ArticleInternational journal of molecular sciences2021
Dysregulated CD38 Expression on Peripheral Blood Immune Cell Subsets in SLE.
Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05362812 (Prediction of Lupus Renal Flares Study), which is not on this map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prediction of Lupus Renal Flares Study
Who cites it
27 citing papers in PubMed, 40 citations in OpenAlex.
- Daratumumab in systemic lupus erythematosus: a single-arm phase 2 trial.Nature communications · 2026Trial
- Anti-CD38 monoclonal antibody CM313 for systemic lupus erythematosus: a randomized, double-blind, placebo-controlled phase Ib/IIa trial.Signal transduction and targeted therapy · 2025Trial
- Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two phase 3 trials.Annals of the rheumatic diseases · 2024Trial
- Mezagitamab in systemic lupus erythematosus: clinical and mechanistic findings of CD38 inhibition in an autoimmune disease.Lupus science & medicine · 2024Trial
- Emerging chemical strategies for CD38 inhibition: restoring NADBioorganic & medicinal chemistry · 2026Review
- Peripheral blood immune cell subsets as non-invasive biomarkers of colorectal cancer stage, laterality, metastasis and survival.Cellular oncology (Dordrecht, Netherlands) · 2026Article
- Two-Sample Bidirectional Mendelian Randomization Analysis of the Causal Relationship Between Immune Cell Phenotypes and Systemic Lupus Erythematosus.Clinical, cosmetic and investigational dermatology · 2026Article
- Linking CD38 Cell Surface Expression to the Unique Calcium Flux Properties in Human Peripheral B Lymphocytes Following anti-IgM and anti-IgG Stimulation.Journal of immunology research · 2026Article
- Single-cell Unperturbed Activation Profiling by mass cytometry capturesFrontiers in immunology · 2026Article
- CyTOF analysis of immune characteristics in cSLE: belimumab treatment and refractory cases.Frontiers in immunology · 2026Article
- Literature review and case study of predominant tubulointerstitial lupus nephritis.Renal failure · 2025Review
- Immune-cell profiling to guide stratification and treatment of patients with rheumatic diseases.Nature reviews. Rheumatology · 2025Review
- Emerging B and plasma cell-targeting immune therapies in idiopathic inflammatory myopathies.Frontiers in immunology · 2025Review
- Systemic lupus erythematosus: pathogenesis and targeted therapy.Molecular biomedicine · 2024Review
- Single-cell mass cytometry in immunological skin diseases.Frontiers in immunology · 2024Review
- Comparative single-cell multiplex immunophenotyping of therapy-naive patients with rheumatoid arthritis, systemic sclerosis, and systemic lupus erythematosus shed light on disease-specific composition of the peripheral immune system.Frontiers in immunology · 2024Article
- Immunotherapeutic approaches for systemic lupus erythematosus: early overview and future potential.Medical review (2021) · 2023Review
- Daratumumab monotherapy for refractory lupus nephritis.Nature medicine · 2023Article
- Mass cytometry uncovers a distinct peripheral immune profile and upregulated CD38 expression in patients with hidradenitis suppurativa.Cellular & molecular immunology · 2023Article
- Dysregulated CD38 expression in blood and skin immune cells of patients with hidradenitis suppurativa.Research square · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Given its uniformly high expression on plasma cells, CD38 has been considered as a therapeutic target in patients with systemic lupus erythematosus (SLE). Herein, we investigate the distribution of CD38 expression by peripheral blood leukocyte lineages to evaluate the potential therapeutic effect of CD38-targeting antibodies on these immune cell subsets and to delineate the use of CD38 as a biomarker in SLE. We analyzed the expression of CD38 on peripheral blood leukocyte subsets by flow and mass cytometry in two different cohorts, comprising a total of 56 SLE patients. The CD38 expression levels were subsequently correlated across immune cell lineages and subsets, and with clinical and serologic disease parameters of SLE. Compared to healthy controls (HC), CD38 expression levels in SLE were significantly increased on circulating plasmacytoid dendritic cells, CD14
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.